About larotrectinib
TRK kinase inhibitor
Used for
- Treats solid tumors with an NTRK gene fusion that cannot be removed or has spread, when no satisfactory alternatives exist.
Usual adult dose
100 mg by mouth twice daily; continue until the cancer progresses or side effects become unacceptable.
Usual dose in children
Children: 100 mg/m² by mouth twice daily, up to 100 mg per dose; dosing depends on body surface area.
Common side effects
- Tiredness
- Dizziness
- Nausea or vomiting
- Constipation or diarrhea
Important warnings
- Can cause nervous-system effects, including dizziness, confusion, or coordination problems.
- Can cause liver injury; liver blood tests are monitored during treatment.
- May harm an unborn baby; effective contraception is recommended during treatment and for one week afterward.
- Doses may need adjustment with liver problems or interacting medicines.
Pregnancy
May cause fetal harm. Human pregnancy data are limited; effective contraception is recommended during treatment and for one week after the last dose.
Breastfeeding
It is not known whether larotrectinib passes into breast milk. Do not breastfeed during treatment or for one week after the last dose.
Interactions
- Strong or moderate CYP3A inhibitors can increase larotrectinib levels.
- Strong or moderate CYP3A inducers can reduce larotrectinib levels.
- Larotrectinib can increase levels of some CYP3A-sensitive medicines, including certain sedatives.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.